Zacks points to Eli Lilly, Novartis and Bayer as 2026 pharma momentum builds

Pharmaceutical stocks are entering 2026 with improving sentiment, according to a Zacks Industry Outlook focused on the group’s larger, diversified players. In coverage distributed via Yahoo Finance, Zacks singled out Eli Lilly, Novartis and Bayer as names it expects to benefit as the sector “rebuilds” in the year.

For Eli Lilly, the bullish framing centers on the idea that investors are looking past near-term volatility and toward a forward product cycle. Zacks’ outlook describes a backdrop of innovative drug pipelines and what it characterizes as strong product demand, both of which are factors that can support ongoing revenue growth.

The outlook also ties sector strength to rising earnings estimates, a measure of how analysts’ expectations can move upward as data accumulates around new medicines, demand trends and pipeline execution. In Zacks’ framing, that improvement in earnings outlook helps explain why select large-cap pharma stocks may continue to attract capital even when broader market conditions remain mixed.

Novartis and Bayer are discussed alongside Lilly, suggesting Zacks’ thesis is not confined to one company’s pipeline. Instead, the argument is presented at the industry level: the pharma sector is rebounding, and multiple companies with meaningful research and development programs are positioned to participate if demand stays firm and earnings expectations keep trending higher.

The coverage does not spell out which specific therapies, trial readouts, or product launches drive the improvement, and it does not provide company-by-company financial guidance figures in the information available here. As a result, the clearest takeaway is directional, reflecting Zacks’ view of momentum rather than a detailed roadmap of catalysts.